In contrast, anti-IFN-γ treatment alone significantly improves hepatosplenomegaly (Fig. 8B–D), while single treatment with anti-IFNAR only improves thrombocytopenia and minimizes the expression of inflammatory cytokines (Il6, Il12b, and Tnfa). Here, IFNAR1 is linked to Hepatosplenomegaly.